Timing Exercise Training as Strategy to Improve Insulin Sensitivity and Substrate Metabolism in Men and Woman With Pre-diabetes
NCT ID: NCT06014684
Last Updated: 2025-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
24 participants
INTERVENTIONAL
2023-07-13
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary study endpoint is nocturnal glucose levels measured by a continuous glucose monitor (CGM).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Timed Exercise and 24h Metabolism
NCT05073068
Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors
NCT05123963
Examining the Effects of Morning and Evening Exercise on Glucose Regulation in Adults With Prediabetes
NCT06292000
Does Exercise Timing Affect Glucose Levels in People With Diabetes?
NCT03626155
Time Efficient Exercise in Type 2 Diabetes
NCT02340260
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: The main objective of this study is to determine whether prolonged exercise training in the afternoon (15:00-17:00 PM) differs from exercise training in the morning (07:00-09:00 AM) in improving insulin sensitivity in individuals with pre-diabetes, and to investigate its underlying mechanisms.
Study design: The present study is a randomized double arm longitudinal intervention study in a pre and post design.
Study population: 24 pre-diabetic individuals (men and postmenopausal women aged 40 - 75 years and with BMI ≥ 25 and ≤ 38 kg/m2) will complete this study (12 participants in the morning training group and 12 participants in the afternoon training group). From experience with similar studies, we estimate a drop-out rate of 20% and a screening failure of 70% (because individuals often do not know they are pre-diabetic). This results in maximally 30 participants that have to be included and 100 participants that have to be screened (maximally).
Intervention (if applicable): Participants will perform a 12-weeks supervised high intensity interval training (HIIT) program with three \~30 min exercise sessions per week. Participants will be randomly assigned to the morning or afternoon training time. To assess the outcomes, participants will come to the university for a 43h measurement period both before and after the 12-week training program.
Main study parameters/endpoints: The primary study endpoint is nocturnal glucose levels measured by a continuous glucose monitor (CGM). The secondary outcomes are 24h energy and substrate metabolism. Exploratory outcomes are body composition, intrahepatic lipid content and composition, hepatic insulin sensitivity, hepatic glycogen levels, maximal aerobic capacity, skeletal muscle oxidative capacity, visceral and subcutaneous adipose tissue volume, sleeping metabolic rate, blood glucose levels (continuously measured over 7days) and immune responses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AM exercise
HIIT program performed between 07:00-09:00 AM
Timing of exercise
High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
PM exercise
HIIT program performed between 15:00-17:00 PM
Timing of exercise
High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Timing of exercise
High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) ≥25 kg/m2
* Male, or postmenopausal (at least 1 year post cessation of menses) female
* Pre-diabetes based on one or a combination of the following criteria:
* Impaired Glucose Tolerance (IGT): plasma glucose values ≥ 7.8 mmol/l and ≤ 11.1 mmol/l 120 minutes after glucose drink consumption during OGTT in screening
* ImpairedFastingGlucose(IFG):Fastingplasmaglucose≥6.1mmol/land≤6.9 mmol/l
* Insulin Resistance: glucose clearance rate ≤ 360 mL/kg/min, as determined during the OGTT using OGIS120.
* HbA1cof5.7-6.4%
Exclusion Criteria
* Patients with active congestive heart failure and and/or severe renal and or liver insufficiency
* Uncontrolled hypertension
* Any contra-indication for MRI scanning
* Alcohol consumption of \>3 servings per day for man and \>2 servings per day for woman
* Smoking
* Unstable body weight (weight gain or loss \> 5kg in the last 3 months)
* Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator which would possibly hamper our study results.
* Medication use known to hamper subject's safety during the study procedures.
* Subjects who do not want to be informed about unexpected medical findings.
* Men: Hb \<8.0 mmol/L, Women: Hb \<7.0 mmol/l
* Heavily varying sleep-wake rhythm (i.e. night shift work and travels across time zones).
* Significant food allergies/intolerance (seriously hampering study meals)
* Blood donation during or within 2 months prior to the study
40 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maastricht University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maastricht University
Maastricht, Limburg, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL83421.068.22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.